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Autophagy is an evolutionarily preserved degradation process of cytoplasmic cellular
constituents, which participates in cell response to disease. We previously characterized
VMP1 (Vacuole Membrane Protein 1) as an essential autophagy related protein that
mediates autophagy in pancreatic diseases. We also demonstrated that VMP1-mediated
autophagy is induced by HIF-1A (hypoxia inducible factor 1 subunit alpha) in
colon-cancer tumor cell lines, conferring resistance to photodynamic treatment. Here
we identify a new molecular pathway, mediated by VMP1, by which gemcitabine is
able to trigger autophagy in human pancreatic tumor cell lines. We demonstrated that
gemcitabine requires the VMP1 expression to induce autophagy in the highly resistant
pancreatic cancer cells PANC-1 and MIAPaCa-2 that carry activated KRAS. E2F1 is
a transcription factor that is regulated by the retinoblastoma pathway. We found that
E2F1 is an effector of gemcitabine-induced autophagy and regulates the expression and
promoter activity of VMP1. Chromatin immunoprecipitation assays demonstrated that
E2F1 binds to the VMP1 promoter in PANC-1 cells. We have also identified the histone
acetyltransferase EP300 as a modulator of VMP1 promoter activity. Our data showed
that the E2F1-EP300 activator/co-activator complex is part of the regulatory pathway
controlling the expression and promoter activity of VMP1 triggered by gemcitabine in
PANC-1 cells. Finally, we found that neither VMP1 nor E2F1 are induced by gemcitabine
treatment in BxPC-3 cells, which do not carry oncogenic KRAS and are sensitive
to chemotherapy. In conclusion, we have identified the E2F1-EP300-VMP1 pathway
that mediates gemcitabine-induced autophagy in pancreatic cancer cells. These
results strongly support that VMP1-mediated autophagy may integrate the complex
network of events involved in pancreatic ductal adenocarcinoma chemo-resistance. Our
experimental findings point at E2F1 and VMP1 as novel potential therapeutic targets in
precise treatment strategies for pancreatic cancer.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one of the most
aggressive human malignancies with 8–9% 5-year survival rate
(1). Despite the progress in the knowledge of the disease, it
remains a calamitous neoplasia. Up to 60% of patients have
advanced pancreatic cancer at the time of diagnosis, and their
median survival time is 3–6 months (2). Its poor prognosis
has been attributed to a tendency regarding early vascular
dissemination and spreading to regional lymph nodes, and to the
incapacity to make a diagnosis while the tumor is still surgically
removable (2). This is caused both by the aggressive nature of
the disease, the lack of specific symptoms and early detection
tools, and the refractory response to traditional cytotoxic agents
and radiotherapy (3, 4). Furthermore, pancreatic cancer cells get
more malignant and survive with an extremely low blood supply
(2, 3). Up to now, contradictory data are available concerning
autophagy activity and its regulation by specific autophagy
related (ATG) proteins in pancreatic cancer cells. Experimental
evidence places autophagy as a mechanism for survival of tumor
cell under adverse environmental conditions, or as a defective
mechanism of programmed cell death that promotes pancreatic
cancer cell resistance to treatment (5–7).
At present, the first option for resectable tumors in pancreatic
cancer is adjuvant chemotherapy before surgical resection
(8, 9). However, most patients are in an advanced stage at
the time of diagnosis and in these cases, chemotherapy is
used as the first option. Regarding chemotherapy, gemcitabine
used alone or in combination with nabpaclitaxel represent
one of the most effective therapy (9, 10), despite its poor
efficacy in terms of overall patient survival (11). Gemcitabine
works by causing apoptosis of malignant cells in pancreatic
cancer (12, 13). Intrinsic and acquired factors are involved in
gemcitabine resistance. Several of them related to the transport
and metabolism of gemcitabine (14) and associated with the
tumor microenvironment, among others (15, 16).
Interestingly, recent studies highlight the importance
of autophagic flux in acquiring resistance to gemcitabine
in pancreatic cancer tumor cells (17–19). Macroautophagy
(hereafter autophagy), is an evolutionarily conserved process
that involves the sequestration and delivery of cytoplasmic
components into the lysosome, where they are degraded and
recycled (20). Autophagy is involved in the turnover of long-
lived proteins and other cellular macromolecules. It has also
been involved in the physiological responses to exercise and
aging and is implicated in different pathophysiological processes
such as neurodegenerative disorders, cardiovascular, pulmonary
Abbreviations: ATG, related to autophagy; ChIP, chromatin
immunoprecipitation; E2F1, E2F transcription factor 1; EGFP, enhanced green
fluorescent protein; EP300, E1A binding protein p300; HIF1A, hypoxia inducible
factor 1 subunit alpha; KRAS, Kirsten rat sarcoma viral oncogene homolog;
LC3, microtubule-associated protein 1 light chain 3; PDAC, pancreatic ductal
adenocarcinoma; PBS, phosphate-buffered saline; RLU, Relative light units; RFP,
red fluorescent protein; shControl, short hairpin RNA with a scrambled sequence;
shE2F1, short hairpin RNA targeting E2F1; shEP300, short hairpin RNA targeting
EP300; shVMP1, short hairpin RNA targeting VMP1; TBS, TRIS-buffered saline;
TTS, transcriptional starting site; VMP1, Vacuole Membrane Protein 1.
diseases, and cancer (21–24). Autophagy correlates with poor
patient outcome in pancreatic cancers (25), and it has been
suggested that autophagy is required for tumor growth (6, 7).
For instance, in mice with pancreas containing an activated
oncogenic allele of KRAS proto-oncogene, GTPase (KRAS),
the most frequent mutation in PDAC (26), a small number
of pre-cancerous lesions are developed that become PDAC
randomly over time (27). KRAS activates the expression of the
Vacuole Membrane Protein 1 (VMP1) to induce and maintain
autophagy levels in pancreatic tumor cells (28). Accordingly,
mice lacking the essential autophagy genes ATG5 or ATG7
acquire pre-invasive low-grade pancreatic intraepithelial
neoplasia lesions, but progression to high-grade pancreatic
intraepithelial neoplasia lesions and PDAC is blocked (27). This
evidence highlight the relevance of KRAS-induced autophagy in
the malignant transformation of pancreatic tumor cells.
Autophagy involves the formation of double-membrane
structure, autophagosomes, around the cellular components
targeted for degradation, which include large structures such as
organelles and protein aggregates (29). Autophagy is mediated by
a set of evolutionarily conserved gene products (termed the ATG
proteins) originally discovered in yeast (30). In mammalian cells,
the sequential association of at least a subset of the ATG proteins,
referred to as the core molecular machinery (29), leads to the
autophagosome formation. VMP1 belongs to these essential
ATG proteins. We have demonstrated that VMP1 expression
triggers autophagy in mammalian cells even under nutrient-rich
conditions (31, 32). By contrast, autophagy is completely blocked
in the absence of VMP1 expression (31). VMP1 autophagy-
related function requires its hydrophilic C-terminal domain
of 20 amino acids (VMP1-ATGD) (32). This domain binds
directly to the Bcl-2 binding domain (BH3) motif of beclin 1
(BECN1) leading to the formation of a VMP1-BECN1-PI3KC3
(phosphatidylinositol 3-kinase catalytic subunit type 3) complex
at the site where autophagosomes are generated (33, 34).
VMP1 is not expressed in normal pancreas, however its
expression is early activated in pancreas suffering experimental
diabetes mellitus, experimental and human pancreatitis, and
in human pancreatic cancer cells (35–39). Interestingly, VMP1
prevents pancreatic cell death induced by acute pancreatitis
(35). In previous studies, we found that VMP1 expression
is induced by mutated KRAS in pancreatic tumor cells (28).
KRAS is a member of the Ras family of GTP-binding proteins
that mediate a wide variety of cellular functions including
proliferation, differentiation, and survival. KRASmutation is one
of the earliest genetic events in human PDAC (40). Besides,
it has been demonstrated that VMP1 down-regulation reduces
cell resistance of pancreatic cells to chemotherapeutic drugs as
Imatinib, Cisplatin, Adriamycin, Staurosporin, and Rapamycin
(41). In colon cancer cells, we have recently shown that the HIF-
1A-VMP1 autophagic pathway is involved in the resistance to
photodynamic therapy in colon cancer cells (42). Therefore, we
hypothesized that VMP1 is involved in the tumor cell response
to chemotherapy in pancreatic cancer cells.
Here, we study the role of autophagy and its molecular
mechanism involved in the pancreatic tumor cell response
to chemotherapy. We identified a new regulatory pathway,
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which is activated in high resistant pancreatic tumor cells,
carrying oncogenic KRAS, under gemcitabine treatment but not
in sensitive cells to chemotherapy. This molecular mechanism
includes the activation of E2F transcription factor 1 (E2F1)
that binds to VMP1 promoter to enhance VMP1-mediated
autophagy.We also identified the histone acetyltransferase EP300
(E1A binding protein p300), as a modulator of this promoter
activity. Our data show that the E2F1-EP300 activator/co-
activator complex is part of the regulatory pathway controlling
VMP1 expression triggered by gemcitabine. Together these data
point at E2F1 as a regulatory factor modulating VMP1-mediated
autophagy in human pancreatic cancer cells and integrate this
degradative cellular process into the complex network of events
involved in PDAC chemoresistance.
MATERIALS AND METHODS
Mammalian Cell Lines, Transfections, and
Treatments
Human pancreatic cancer cell lines with mutated KRAS, PANC-
1 (KRASG12D), and MIAPaCa-2 (KRASG12C), and human
pancreatic cancer cell line with wild type KRAS, BxPC-
3 (43), and also a human HeLa cell line were obtained
from American Type Culture Collection. PANC-1, MIAPaCa-
2, and HeLa cells were cultured in Dulbecco’s modified Eagle’s
medium (Biological Industries) containing 10% fetal bovine
serum (Natocor). BxPC-3 cells were cultured in RPMI 1640
medium (Biological Industries) containing 10% fetal bovine
serum (Natocor). All cell culture mediums were supplemented
with 100 U µl−1 penicillin, and 100 µg µl−1 streptomycin
(Biological Industries). All cell lines were maintained at 37◦C
under a humidified atmosphere with 5% CO2. Mycoplasma
contamination is periodically checked by PCR, each time a cell
line enters the laboratory, and then monthly for each cell line
currently in use. Cells were seeded 24 h before transfection and
treatments to reach a 60% confluence. Cells were transfected
using FuGENE-6 Transfection Reagent (Promega) as indicated
by the manufacturer. Gemcitabine (Elli Lilly) and chloroquine
(Sigma-Aldrich) were prepared according to the manufacturer’s
instructions. Cells were treated with 20µM gemcitabine (Elli
Lilly) and/or 10µM chloroquine (Sigma) for different times
when appropriate.
Expression Vectors
Plasmid pRFP-LC3 (microtubule-associated protein 1 light
chain 3 fused to red fluorescent protein) was kindly provided
by Dr. Maria I. Colombo [Universidad Nacional de Cuyo,
Consejo Nacional de Investigaciones Científicas y Técnicas
(CONICET), Argentina]. The vector pEGFP-VMP1 (enhanced
green fluorescent protein fused to VMP1) was designed and
constructed as previously reported (31). Expression vector for
E2F1 was kindly provided by Dr. Cánepa (Facultad de Ciencias
Exactas y Naturales, Universidad de Buenos Aires, Argentina).
The expression vector Flag-EP300 was kindly provided by Dr.
Donald Tindall (Mayo Clinic, Rochester, MN, USA). The shRNA
targeting EP300 (shEP300) was obtained from Sigma-Aldrich (St.
Louis, MO). VMP1 and E2F1 down-regulation was made using
the plasmid pCMS3-1p-EGFP, which was kindly provided by Dr
D. Billadeau (Department of Immunology, College of Medicine,
Mayo Clinic, USA), and contains a separate transcriptional
cassette for EGFP to identify transfected cells. A plasmid contains
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regulation. A vector with a scramble sequence was used as a
control short hairpin RNA (shControl).
Cell Viability Assay by Trypan Blue Method
Cells were seeded into 6-well-plates at 1× 105 cells per well with
3ml growth medium. The following day, PANC-1, MIAPaCA-
2, and BxPC-3 cells were treated with 20, 200, or 2,000µM
gemcitabine for 24, 48, and 72 h. The number of viable cells was
then determined by the Trypan blue method. Cells were raised
by gentle pipetting into the growth medium, and 0.5ml of the
cell suspension was taken and mixed with 0.5ml of a Trypan
Blue 0.2% w/v in phosphate-buffered saline (PBS) solution and
incubated for 3min at room temperature. Colored (dead) and
non-colored (live) cells were counted in a Neubauer chamber.
The percentage of viable cells under gemcitabine treatment
regarding to control was determined according to the following
formula: %Viable cells=NT/NC× 100, where NC is the number
of viable cells in the control and NT is the number of viable cells
under treatment at the same time of incubation.
RNA Extraction and Quantitative
Real-Time PCR (qPCR)
Cells lines were grown in 6-well-plates at 3.5 × 105 cells per well
with 3ml growth medium. After the corresponding transfections
and treatments, RNA extraction from cell cultures was performed
with the TRIzol reagent (Invitrogen). The concentration of
RNA was determined by Vision Life Science Spectrophotometer
(Hoefer) and RNA was running in an agarose gel to check its
quality. RNA purified (2 µg) were used and treated with 1 µl
of RNase-free DNase I (Invitrogen) in a final volume of 10
µl containing 1X DNAse (deoxyribonuclease) buffer. The 10
µl of DNAse treatment was incubated with 100 nM random
primers (N6) at 70◦C for 5min. Then, 1X MMLV buffer, dNTPs
(deoxynucleoside triphosphates) to 1mM and 1µl of the enzyme
MMLV reverse transcriptase (Promega) were added in a final
volume of 20 µl, incubated at 25◦C for 5min and then at 37◦C
for 1 h (RT). The RT-PCR reaction was performed on a Techne
cycler. For the qPCR, the primers described below were used with
0.5 µl of RT per reaction in a final volume of 25 µl using the
Master Mix Real Mix (Biodynamics). The qPCR was performed
on RG 6000 cycler (Corvette). The cycling conditions were as
follows: 95◦C for 2min followed by 40 cycles of 95◦C for 20 s,
58◦C for 20 s, and 72◦C for 30 s. Transcript level of VMP1
mRNA was normalized by comparison with mRNA of β-actin
and was calculated using the 2−11CT method (44, 45). Specific
primers were used for VMP1: forward 5
′
-GGTGCTGAACCA
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Cells were seeded into 60mm culture dishes at 8 × 105 cells
per dish with 5ml growth medium. After different treatments
and transfections, cells were lysed in ice-old RIPA buffer
(150mM NaCl, 1% Triton X-100, 1% sodium deoxycholate,
0.1% SDS, 10mM Tris-HCl pH 7.2, 5mM EDTA) containing
Phosphatase and Protease Inhibitor Cocktail (Sigma–Aldrich).
Protein concentration was determined using the bicinchoninic
acid (BCA) protein assay reagent (Pierce). Equal amount
of protein was analyzed on SDS-PAGE and transferred to
polyvinylidene fluoride PVDF membranes (0.22µm pore size,
Millipore). The membranes were blocked with Odyssey Blocking
Buffer (LI-COR) at room temperature for 1 h and incubated
with the corresponding primary antibodies overnight at 4◦C. The
primary antibodies used were anti-VMP1 (1:1,000; rabbit mAb
#12929, Cell Signaling Technology), anti-E2F1 (1:500; mouse
mAb CS204394; Millipore), anti-Actin (1:4,000; rabbit polyAb
A2066; Sigma–Aldrich). After incubation, the membrane was
washed four times with PBS containing 0.1% Tween-20 (PBST)
and twice with PBS, and then incubated with the corresponding
IRDye secondary antibody (1:15,000, IRDye R© 680LT Goat anti-
Rabbit IgG or 1:10,000, IRDye R© 800CW Goat anti-Mouse IgG,
LI-COR) in Odyssey Blocking Buffer (LI-COR) for 2 h at room
temperature. After, the membrane was washed four times with
PBST, twice with PBS, and scanned with Odyssey R© SA (LI-
COR). For LC3 western blotting, the membranes were blocked
with 5% (w/v) non-fat dry milk in TRIS-buffered saline (TBS)
containing 0.1% Tween-20 (TBST) at room temperature for 1 h
and incubated with the primary antibody anti-LC3B (1:1,000,
Rabbit mAb #3868, Cell Signaling Technology) overnight at 4◦C.
After the incubation, the membrane was washed four times
with TBST and twice with TBS, then incubated with anti-rabbit
HRP-conjugated (1:3,000, Amersham NA934, GE Healthcare)
secondary antibody in TBST with 5% (w/v) non-fat milk for 2 h
at room temperature. Next, themembrane was washed four times
with TBST and twice with TBS and incubated with PIERCE ELC
Plus Western blotting Substrate (Cat# 32134, Thermo Scientific)
according to manufacturer’s instructions. Finally, the membrane
was scanned with cDigit Blot Scanner (LI-COR). We used
ImageJ software to determine protein bands density. Relative
densitometry normalized to actin is expressed as the mean ± SD
of three different experiments.
Fluorescence Microscopy
To determine autophagy, cells were growing on glass slides into
24-well-plates. They were seeded at 5 × 104 cells per well with
1ml growth medium. Twenty-four hours later, cells were co-
transfected with a red fluorescent protein fused to LC3 (RFP-
LC3) expression vector and the indicated plasmid, and then
treated with gemcitabine. Next, cells were fixed with 4% p-
formaldehyde in PBS for 15min, and immediately washed several
times with PBS. Samples were mounted in DABCO (Sigma–
Aldrich) and observed using a fluorescence microscope Nikon
Eclipse 200 (Plan100), or an inverted LSM Olympus FV1000
using an UPLSAPO 60X O NA: 1.35 objective. We consider a
cell positive for autophagy when RFP-LC3 has a punctate staining
and not diffused protein remains. The number of fluorescent cells
with punctate staining per 100 fluorescent RFP-LC3 transfected
cells was determined in three independent experiments. To
quantify, the number of fluorescent cells with punctate staining
was counted in six random fields representing 100 fluorescent
cells and expressed as the mean± SD of combined results.
In silico Analysis
Genomic details and characteristics from human VMP1 gene
were collected from the Ensembl Genome database. VMP1
promoter prediction was done using the Gene2Promoter utility;
transcription factors binding sites and additional information
was obtained using RegionMiner, MatBase, and MatInspector
tools (Genomatix Software). Supporting evidence was found
using the Neural Network Promoter Prediction program
(BDGP version 2.2) and FPROM (Softberry). Alibaba 2.1 and
PROMO 3.0 were also used for transcription factors’ consensus
sequences search.
Cloning of VMP1 Promoter Into Reporter
Vector
Genomic DNA from HeLa cells was extracted using TRIzol
reagent (Invitrogen). PCR was performed to amplify a fragment
of 3,005 bp and then three progressively shorter ones of
1,977, 1,469, and 883 bp from the 5
′
upstream region of
VMP1 using specific primers and HeLa DNA as template.
PCR was done in a final volume of 50ml as follows: 1×
Pfu DNA Polymerase Buffer (with MgSO4), 300mM dNTPs
(deoxynucleosyde triphosphates), 0.4mM Primers sense/anti-
sense, 50 ng genomic DNA, 1.5U Pfu DNA Polymerase
(Promega). Amplification was performed according to an initial
denaturation step of 1.5min at 94◦C, followed by 30 cycles at
94◦C for 30 s, 59◦C for 30 s, 73◦C for 8min, and a final step
at 73◦C for 5min. PCR products were run in agarose gels and
amplicons were recovered with a Gel Band Purification Kit (GE
Healthcare). Primers had restriction sites for SalI (Forward)
and HindIII (Reverse) enzymes for subsequent cloning of the
fragments in pGemT easy vector (Promega). Amplicons integrity
was confirmed by sequence analysis (MacroGen). All constructs
were then subcloned in the luciferase reporter pGL3 Basic
Vector (Promega), with SalI and HindIII enzymes. As a result,
the constructs pGL3.vmp1-883, pGL3.vmp1-1469, pGL3.vmp1-
1977, and pGL3.vmp1-3005 were obtained.
Luciferase Reporter Assays
For luciferase assays cells were plated 24 h before transfection
in 12-well-plates at 1.4 × 105 cells per well. Cells were used at
60% confluence for pGL3.vmp1 promoter constructs transfection
with FuGENE6 Transfection Reagent (Promega). Ratio used
in each case was 1.5ml FuGENE6 per 1mg DNA. When two
plasmids were transfected, we used 0.4mg of pGL3 reporter and
0.6mg of expression vector. In shRNA assays we used 1.5mg
of shRNA and 0.5mg pGL3 reporter vectors. Treatments were
done 24 h after transfection. In co-transfection experiments with
Frontiers in Endocrinology | www.frontiersin.org 4 June 2020 | Volume 11 | Article 411
Ropolo et al. Gemcitabine-Induced Autophagy in Pancreatic Cancer
FIGURE 1 | Relative sensitivity of pancreatic cancer cell lines PANC-1, MIAPaCa-2 and BxPC-3 to gemcitabine treatment. The number of viable cells was determined
by the trypan blue dye exclusion test. (A) Cells were treated with increasing concentrations of gemcitabine (from 20 to 2,000 µM) for 24 h. BxPC-3 cells are sensitive
to all gemcitabine concentrations tested, and PANC-1 and MIAPaCa-2 cells are sensitive from 200 µM gemcitabine. (B) Cells were treated with 20 µM gemcitabine
and cell viability was determined at 0, 12, 24, 48, and 72 h. There were no significant differences within 72 h of treatment in PANC-1 cells, and within 48 h of treatment
in MIAPaCa-2 cells. However, a significant reduction in cell viability was observed in BxPC-3 cells from 12h of treatment. Results are presented as percentage of
viable cells compared to the untreated control (mean ± SE; n = 3). *p < 0.05 vs. untreated cells, **p < 0.01 vs. untreated cells.
expression vectors, cells were processed 48 h after transfection.
Each condition was tested in triplicate. Cells were washed with
cold PBS and lysed with 100ml of 1× Cell Culture Lysis Buffer
(Promega). 96-well-plates were used for activity assays. In each
well 40 µl of luciferase substrate was added to 20 µl of lysate
and a 5-s reading was done for luminescence measurement in
a Victor3 1420 multilabel counter (PerkinElmer). Results were
normalized to protein concentration. Relative light units (RLU)
value was calculated as luciferase activity/protein concentration.
Chromatin Immunoprecipitation (ChIP)
Assay
Chromatin immunoprecipitation was conducted following the
Pierce Agarose Chip kit (Thermo Scientific). Briefly, PANC-
1 cells were culture into 100mm culture dishes at 3 × 106
cells per dish with 13ml growth medium. The next day, cells
were treated with 20µM gemcitabine and 24 h were cross-linked
with 1% formaldehyde directly into the media for 10min at
room temperature. The cells were then washed and scraped
with PBS and collected by centrifugation at 800 × g for
5min at 4◦C, resuspended in cell lysis buffer and incubated
on ice for 15min. The pellet was then resuspended in nuclear
lysis buffer and sheared to fragment DNA to about 700 bp.
Samples were then immunoprecipitated using a E2F1 antibody
or normal rabbit IgG (Millipore) overnight at 4◦C on a rotating
wheel. Following immunoprecipitation, samples were washed
and eluted using the chromatin immunoprecipitation kit in
accordance with the manufacturer’s instructions. Cross-links
were removed at 62◦C for 2 h followed by 10min at 95◦C
and immunoprecipitated DNA was purified and subsequently
amplified by PCR. PCR was performed using seven primer
sets for the seven areas containing potential E2F1 binding































































PCR products were visualized on a 2% agarose gel.
Statistical Analysis
Data are expressed as mean ± SD. We performed a minimum
of three independent experiments, where individual data points
were based on at least technical duplicates each. Student’s t-test
was used for comparisons between two groups and ANOVA
test to assess more than two groups. P < 0.05 were considered
statistically significant. Statistical analysis of data was performed
using GraphPad Prism 6.
RESULTS
Gemcitabine Requires VMP1 Expression to
Induce Autophagy in Pancreatic Cancer
Cells Carrying Oncogenic KRAS
In order to analyze the time course effect of gemcitabine
treatment on VMP1 expression we used PANC-1 and MIAPaCa-
2 pancreatic tumor cells harboring a KRAS activating mutation,
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FIGURE 2 | Gemcitabine requires VMP1 expression to induce autophagy in PANC-1 and MIAPaCa-2 cells. PANC-1 and MIAPaCa-2 cells were treated with 20 µM
gemcitabine for 12 and 24 h. (A) qPCR and western blot analysis showed an increase of VMP1 mRNA (A) and protein expression (B) in PANC-1 and MIAPaCa-2 cells
under treatment (n = 3). (B) Western blot analysis shows an increase of in PANC-1 and MIAPaCa-2 cells submitted to gemcitabine treatment. (C) Relative
densitometry (VMP1/Actin and LC3-II/Actin) of western blots are shown in panel (B) (n = 3). (D) PANC-1 and MIAPaCa-2 cells were transiently co-transfected with
RFP-LC3 and shVMP1-EGFP or shControl-EGFP expression vectors, and they were treated with 20 µM gemcitabine for 24 h. RFP-LC3 distribution was detected
using fluorescence microscopy. Representative images show the punctate RFP-LC3 in cells expressing EGFP (bar scale = 10µm). Quantitation represents the
percentage of RFP-LC3 cells with punctate staining. LC3 redistribution was significantly reduced in shVMP1 expressing cells under gemcitabine treatment in both cell
lines (*p < 0.05 vs. gemcitabine-treated shControl transfected cells). (E) PANC-1 and MIAPaCa-2 cells were transfected with the shControl or shVMP1 expression
vectors. VMP1 expression was reduced by shVMP1 in PANC-1 and MIAPaCa-2 cells as was demonstrated by western blotting. Relative densitometry (VMP1/Actin) is
shown (n = 3). *p < 0.05, **p < 0.01.
that are highly resistant to chemotherapy, and BxPC-3 pancreatic
tumor cells that do not carry KRAS mutation. The relative
sensitivity of pancreatic cancer cells to gemcitabine treatment
was analyzed. PANC-1, MIAPaCa-2, and BxPC-3 cells were
treated with 20, 200, and 2,000µM gemcitabine. The relative
number of viable cells was determined by the trypan blue dye
exclusion test 24 h later. Figure 1A shows cell viability as a
percentage relative to control according to the gemcitabine dose.
BxPC-3 cells were more sensitive in all doses of gemcitabine
analyzed (Figure 1A). However, cell viability was significantly
reduced from 200 µM gemcitabine in PANC-1 and MIAPaCa-
2 cells (Figure 1A). Thus, gemcitabine 20 µM is the lowest
tested dose in which BxPC-3 cells are sensitive, and PANC-1
and MIAPaCa-2 are resistant, at least 24 h after treatment. In
view of this, we analyzed cell viability of PANC-1, MIAPaCa-2,
and BxPC-3 cells under 20 µM gemcitabine treatment during
72 h. There were no significant differences during the 72 h of
treatment for PANC-1 cells and up to 48 h of treatment for
MIAPaCa-2 cells. On the other hand, BxPC-3 cells showed a
significant reduction in cell viability from 12 h of treatment
(Figure 1B). These results indicate that at 12 and 24 h with 20
µM gemcitabine, PANC-1 and MIAPaCa-2 cells are resistant,
and by comparison, BxPC-3 cells are sensitive to treatment.
Consequently, from now on we use this dose of gemcitabine for
the following experiments.
Next, PANC-1 and MIAPaCa-2 cells were incubated
with 20µM gemcitabine for 24 h and we evaluated VMP1
mRNA expression by qPCR assays. A significant induction
of VMP1 mRNA was found after 12 and 24 h of gemcitabine
treatment in PANC-1 and MIAPaCa-2 cells (Figure 2A).
LC3 is currently used as a specific marker of autophagy
(46). During the autophagic process, the cytosolic form
of LC3 (LC3-I) undergoes C-terminal proteolytic and
lipid modifications (LC3-II) and translocates from the
cytosol to the autophagosomal membrane (47, 48). Then,
we analyzed VMP1 expression and LC3 lipidation to
determinate autophagy by western blot. Figure 2B shows
that gemcitabine induced VMP1 protein expression and
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LC3-II formation, and therefore autophagy, in PANC-1 and
MIAPaCa-2 cells. The quantification of western blots is shown
in Figure 2C.
Afterward, PANC-1 andMIAPaCa-2 cells were co-transfected
with RFP-LC3 and shVMP1 expression vectors and treated
with 20µM gemcitabine for 24 h. A diffuse pattern of LC3-
RPF expression in the cytoplasm indicates that autophagy is
not occurring, and when autophagy is induced RFP-LC3 is
relocated as dots indicating the formation of autophagosomes.
We counted cells with punctate RFP-LC3 staining to determinate
autophagy (46). Figure 2D shows that gemcitabine induced
RFP-LC3 redistribution to autophagosomes was significantly
reduced when VMP1 expression was down-regulated in both
cell lines. Figure 2E shows downregulation of VMP1 by
shVMP1 expression in PANC-1 and MIAPaCa-2 cell lines.
Therefore, gemcitabine requires VMP1 expression to induce
autophagy in pancreatic tumor cells harboring a KRAS
activating mutation.
Gemcitabine Induces E2F1 Activation of
VMP1-Mediated Autophagy Only in
Pancreatic Tumor Cells That Carry
Oncogenic KRAS
Following, in order to analyze VMP1 expression and autophagy
in cells that carry wild type KRAS, BxPC-3 cells were incubated
with 20µM gemcitabine for 24 h. Interestingly, gemcitabine
treatment did not increase VMP1 mRNA and protein levels
compared to basal conditions in BxPC-3 cells (Figures 3A,B).
Then, we analyzed LC3 lipidation to determinate autophagy,
and western blot analyses shows that gemcitabine treatment did
not induce autophagy evidenced by LC3-II formation in BxPC-
3 cells (Figure 3B). In addition, choloroquine treatment was
used to evaluate autophagic process by inhibiting autophagy
flux (46). The use of chloroquine alone or in combination with
gemcitabine treatment induced LC3-II accumulation compared
to control cells or cells only treated with gemcitabine in the
same proportion, respectively, indicating that gemcitabine did
not interrupt autophagy flux in these cells. The quantification of
western blots is shown in Figure 3C. These results suggest BxPC-
3 cells have a basal VMP1 expression and autophagy that are not
up-regulated by gemcitabine.
E2F transcription factors are involved in cell proliferation
and DNA repair (49). As gemcitabine incorporation into DNA
is critical for its toxicity (50), we evaluated E2F1 expression in
response to gemcitabine treatment. To characterize this response
of E2F1 to gemcitabine, we chose the sensitive cell line BxPC-3
and themost resistant to treatment by comparison, PANC-1 cells.
Western blot assay shows E2F1 protein levels were significantly
increased after 12 and 24 h of gemcitabine treatment in PANC-
1 cells, and they were similar with respect to control in treated
BxPC-3 cells (Figure 3D). In consequence, E2F1 is a candidate to
mediate increased VMP1 expression and autophagy in response
to gemcitabine in PANC-1 but not in BxPC-3 cells.
Considering that VMP1 expression induces autophagosome
formation (31), we tested whether E2F1 expression is capable
of inducing VMP1 expression and autophagy in PANC-1
cells. We performed qPCR on samples from cells transfected
with an expression vector for E2F1. As seen in Figure 3E,
E2F1 expression induced VMP1 mRNA expression in PANC-1
tumor cells. Then, PANC-1 cells were concomitantly transfected
with an expression plasmid encoding for the RFP-LC3 fusion
protein and E2F1 expression vector. Figure 3F shows the
recruitment of LC3 fusion protein in punctate structures in
E2F1-transfected cells in contrast to the diffuse RFP-LC3 fusion
protein signal observed in control cells. Quantitation showed
that recruitment of LC3 was significantly increased in cells
expressing E2F1 compared to control cells (Figure 3F). These
results demonstrate that E2F1 is capable of inducing VMP1
expression and autophagy in pancreatic tumor cells resistant to
gemcitabine treatment.
VMP1 Promoter Is Activated by
Gemcitabine
We have previously demonstrated that starving conditions and
rapamycin treatment induce VMP1 expression inHeLa cells (31).
On the other hand, VMP1 expression is activated in PANC-
1 human tumor cells carrying mutated (G12D) KRAS (28). In
order to study the molecular mechanism that regulates VMP1
expression in the context of gemcitabine induced-autophagy in
pancreatic tumor cells, a 3,005 bp sequence of the 5
′
upstream
region of the human gene VMP1 was amplified and cloned
in the pGL3 reporter vector (pGL3.vmp1-3005) (Figure 4A).
Following, we analyzed if this sequence cloned has a promoter
activity. In these experiments, we used HeLa cells under starving
conditions and rapamycin treatment as a positive control of
autophagy induction, and the pGL3.vmp1-3005 construct was
used to perform luciferase reporter assays. As a result, we found
increased VMP1 mRNA expression and VMP1 promoter activity
in response to starving conditions and to rapamycin treatment
in PANC-1 and HeLa cells (Figures 4B,C). Next, we analyzed
if gemcitabine was able to increase VMP1 promoter activity.
Figure 4D shows that the activity of the 3,005 bp sequence of
VMP1 promoter was significantly increased when PANC-1 and
HeLa cells were treated with 20µM gemcitabine for 24 h.
In order to localize the essential promoter sequence in the
3,005 bp sequence of the 5
′
upstream region of the human
gene VMP1, we amplified and subcloned consecutive shorter
fragments of this region. Three more constructs were created
and named as follows: pGL3.vmp1-1977, pGL3.vmp1-1469, and
pGL3.vmp1-883 (Figure 4E). Luciferase activity assays were
performed in HeLa cells transfected with each construct and
submitted to starvation, rapamycin, or gemcitabine treatment.
Relative promoter activity was analyzed for each sequence
(Figure 4F). Results showed a decreased activation for the
pGL3.vmp1-1977 and pGL3.vmp1-1469 constructs comparing to
the initial 3,005 bp sequence. On the other hand, the activity
was increased when the shorter pGL3.vmp1-883bp construct
was used. The same results were observed in all the conditions
analyzed. These data suggest that essential regulation motifs
involved in VMP1 expression are contained into this VMP1
shorter promoter region of 883 bp.
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FIGURE 3 | Gemcitabine induces E2F1 activation of VMP1-mediated autophagy only in pancreatic tumor cells that carry oncogenic KRAS. qPCR and western blot
analysis showed no significant differences of VMP1 mRNA (A) and protein expression (B) in BxPC-3 treated with 20µM gemcitabine for 12 and 24 h (n = 3).
(B) Western blot analysis shows no difference of VMP1 expression and LC3 lipidation in BxPC-3 cells submitted to gemcitabine treatment. The use of chloroquine
alone or in combination with gemcitabine treatment induced LC3-II accumulation compared to control cells or cells only treated with gemcitabine in the same
proportion, respectively, indicating that gemcitabine does not interrupt autophagy flux in these cells. (C) Relative densitometry (VMP1/Actin and LC3-II/Actin) of
western blots shown in B (n = 3). (D) Western blot analysis shows that E2F1 expression was increased in PANC-1 cells submitted to gemcitabine treatment for 12
and 24 h, and there were no significant differences in the expression of E2F1 in BxPC-3 cells. Relative densitometry (E2F1/Actin) of western blots is shown (n = 3).
PANC-1 cells were transiently transfected with E2F1 expression vector or empty vector as control. (E) qPCR assay demonstrated an increase of VMP1 mRNA
expression in PANC-1 cells expressing E2F1 compared to control cells (n = 3). (F) E2F1 expression induced autophagy as was determined by counting cells with
punctate RFP-LC3 staining. Representative images of RFP-LC3 distribution using confocal microscopy are shown (bar scale = 10µm). The graph presents the
percentage of RFP-LC3 cells with punctate staining (n = 3). *p < 0.05, **p < 0.01.
E2F1 Directly Activates the VMP1 Promoter
and Regulates VMP1 Expression Under
Gemcitabine Treatment
Considering that maximal promoter activity in luciferase
reporter assays was observed for the pGL3.vmp1-883 construct,
we analyzed this sequence using bioinformatics tools. This in
silico analysis data showed a putative promoter in this sequence
containing a TATA. In addition, we identified several putative
binding sites for relevant transcription factors related to the
cellular stress response including E2F1 (Figure 5A).
In order to know if VMP1 gene is a direct target
of E2F1, we used a combination of transcriptional and
chromatin assays to determine a possible involvement of
E2F1 transcription factor in VMP1 promoter activation. First,
we performed luciferase reporter assays using the shorter
sequence of VMP1 promoter, pGL3.vmp1-883bp construct.
Reporter studies demonstrate that expression of E2F1 led
to an increase in VMP1 promoter activity (Figure 5B).
Moreover, endogenous E2F1 can bind to VMP1 promoter in
PANC-1 cells treated with gemcitabine as demonstrated by
ChIP assay (Figure 5C). Also, gemcitabine increased VMP1
promoter activity (see shControl transfected PANC-1 cells)
(Figure 5D). Moreover, down-regulation of E2F1 expression in
PANC-1 cells treated with gemcitabine significantly reduced
VMP1 promoter activity (Figure 5D) and VMP1 expression
(Figure 5E). These results demonstrate that VMP1 is a
novel direct target of the E2F1 transcription factor under
gemcitabine treatment.
E2F1 and EP300 Cooperate in VMP1
Promoter Activation
Transcription factors regulate gene expression through their
inherent activation or repression properties, and through
functional interactions with co-regulatory molecules. Here,
we tested whether activation by E2F1 involves the histone
acetyltransferases EP300. First, we analyzed if EP300 could
induce VMP1 mRNA expression in PANC-1 cells. Figure 6A,
shows that VMP1 mRNA expression was up-regulated in
PANC-1 cells expressing EP300. Additionally, EP300 expression
significantly activated the VMP1 promoter compared to control
cells (Figure 6B). Then, we evaluated if EP300 participates
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FIGURE 4 | VMP1 promoter analysis. (A) To assay VMP1 promoter activity, a 3,005 bp sequence of the 5
′
upstream region of the VMP1 gene was amplified and
cloned into the pGL3 reporter vector (pGL3.vmp1-3005) driving Luciferase (Luc) expression. (B) qPCR assay showed an increase of VMP1 mRNA expression in HeLa
and PANC-1 cells submitted to starving conditions and rapamycin treatment for 4 h (n = 3). Next, HeLa and PANC-1 cells were transfected with pGL3.vmp1-3005.
(C) Relative Luciferase activity shows an increase of VMP1 promoter activation in HeLa and PANC-1 cells submitted to starving (Stv) conditions and rapamycin (Rapa)
treatment. (n = 3). (D) Relative Luciferase activity shows an increase of VMP1 promoter activation in HeLa and PANC-1 cells submitted to gemcitabine treatment for
24 h (n = 3). (E) Consecutive shorter fragments of 3005 bp sequence of VMP1 promoter were amplified and subcloned in the pGL3 reporter vector
(pGL3.vmp1-1977, pGL3.vmp1-1469, pGL3.vmp1-883). (F) HeLa cells were submitted to starvation conditions, rapamycin and gemcitabine treatment for 24 h.
Relative Luciferase activity showed higher levels of VMP1 promoter activation in the shorter construct (pGL3.vmp1-883) compared to 3,005 bp sequence of VMP1
promoter in all treatments. *p < 0.05.
with E2F1 in VMP1 promoter activation. Interestingly, down-
regulation of EP300 impaired E2F1-mediated activation
of the VMP1 promoter in PANC-1 cells (Figure 6C).
Furthermore, co-expression of E2F1 and EP300 led to a
synergistic activation of the VMP1 promoter (Figure 6D). These
findings demonstrate that E2F1 and EP300 cooperates in VMP1
promoter regulation.
Altogether, these data show that the E2F1-EP300 activator/co-
activator complex is part of the novel signaling pathway
controlling the promoter activity and, consequently, the
expression of the autophagy-related gene VMP1 in pancreatic
tumor cells carrying oncogenic KRAS.
DISCUSSION
Tumor cells with a high prevalence of KRAS activating
mutations, like pancreatic cancer, have the distinction of a
poor prognosis (4). Previously, it has been demonstrated
that many human cancer cell lines with KRAS activating
mutations have basal levels of autophagy (51, 52). Yang et al.
(6), have showed that pancreatic cancer cells exhibit constitutive
autophagy under basal conditions, and it is increased in
the advanced stages of PDAC being required for malignant
transformation. In a previous work, we have identified VMP1
as a transcriptional target of oncogenic KRAS signaling
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FIGURE 5 | E2F1 binds to VMP1 promoter and regulates VMP1 expression induced by gemcitabine. (A) Bioinformatics analysis of the VMP1 promoter identified
candidate E2F1 binding sites. TSS, transcription starting site. (B) PANC-1 cells were transiently transfected with pGL3.vmp1-883, E2F1 expression vector or empty
vector as control. Relative luciferase activity showed an increase of VMP1 promoter activation in PANC-1 cells expressing E2F1 compared to control (n = 3). (C) ChIP
assay using chromatin extracts precipitated with an antibody against E2F1 or IgG as a negative control in PANC-1 cells treated with 20µM gemcitabine for 24 h.
Through PCR we amplified the region of VMP1 promoter in anti-E2F1 precipitated products using a specific set of primers (vmp1 Fw and vmp1 Rv) as described in
Experimental Procedures, indicating that E2F1 binds directly to the VMP1 promoter. (D) PANC-1 cells were transiently transfected with shControl or shE2F1
expression vectors and treated with 20µM gemcitabine for 24 h. Relative Luciferase activity showed a significant reduction of VMP1 promoter activation in PANC-1
cells expressing shE2F1 and treated with 20µM gemcitabine for 24 h (n = 3). (E) Western blot analysis showed reduction of VMP1 expression in PANC-1 cells
transfected with shE2F1 targeting vector and treated with 20µM gemcitabine for 24 h. Relative densitometries (VMP1/Actin and E2F1/Actin) of western blots are
shown (n = 3). *p < 0.05, **p < 0.01.
pathway and demonstrated that KRAS requires VMP1 to
induce and maintain basal autophagy in pancreatic tumor
cells (28). On the other hand, VMP1-mediated autophagy
is early induced above basal conditions by gemcitabine
treatment in MIAPaCa-2 cells (36). Moreover, VMP1 is highly
expressed in poorly differentiated human pancreatic cancer
(41). In this study, we identified a regulatory pathway, which
is activated by gemcitabine treatment, in pancreatic tumor
cells carrying a KRAS mutation at amino acid position 12.
This molecular mechanism involves a novel E2F1-EP300-
VMP1 pathway controlling VMP1 expression triggered
by gemcitabine.
According to the Ensembl Genome database, VMP1 gene
is localized in Chromosome 17 of the human genome. Using
informatics tools, we found out four putative promoter regions
given for VMP1 gene; among them we particularly focus
on one of 821 bp localized in the positive strand at the
following position 57784363–57785183 of chromosome 17. In
the analysis, it was also found the proposed transcription-
starting site (TSS) (Figure 5A) at position 501 of the promoter
area. This prediction would regulate the expression of a
12 exons transcript and we consider this transcript to be
the one coding for the 406 aa protein VMP1. The TSS is
located at the start of the first exon sequence, while the
starting codon (ATG) is in the second exon. Considering
these data, we amplified and cloned a 3,005 bp sequence of
the 5
′
upstream regions of the VMP1 gene sequence which
includes the promoter area analyzed above. Using luciferase
reporter assays we demonstrated that this region is activated
by previously reported VMP1 stimuli, such as rapamycin,
starvation, and gemcitabine (Figure 4). We found that regulatory
motifs involved in VMP1 expression are contained into an 883
bp fragment in the 5
′
upstream region of the VMP1 gene.
This essential promoter sequence showed the highest activation
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FIGURE 6 | E2F1 and EP300 cooperates in VMP1 promoter regulation. PANC-1 cells were transiently transfected with an EP300 expression vector or with and empty
expression vector. (A) VMP1 mRNA increased expression was observed by qPCR. In PANC-1 transfected with an EP300 expression vector compared to control cells
(n = 3). (B) PANC-1 cells were transiently transfected with pGL3.vmp1-883. Relative Luciferase activity showed a significant increase of VMP1 promoter activation in
PANC-1 cells co-transfected with EP300 expression vector compared to cells transfected with a control vector (n = 3). (C) PANC-1 cells were transiently
co-transfected with pGL3.vmp1-883, an E2F1 expression vector and shEP300 targeting vector or shControl targeting vector. Relative Luciferase activity showed a
reduction of VMP1 promoter activity in PANC-1 cells co-transfected with E2F1 and shp300 targeting vector compared to cells transfected with a E2F1 and shControl
targeting vector (n = 3). (D) PANC-1 cells were transiently co-transfected with pGL3.vmp1-883, E2F1, and EP300 expression vectors. Relative Luciferase activity
showed an increase of VMP1 promoter activation in PANC-1 cells co-transfected with E2F1 and EP300 expression vectors compared to cells transfected with a E2F1
expression vector alone (n = 3). (E) Schematic model. E2F1-p300-VMP1 pathway that mediates gemcitabine-induced autophagy in pancreatic cancer cells. *p <
0.05, **p < 0.01.
by rapamycin, starvation, and gemcitabine treatment using
luciferase reporter assays.
The in silico analysis of VMP1 essential promoter sequence
revealed the presence of binding sites for several transcription
factors related to cellular stress. We focus our attention
on E2F1 because it has been correlated with high-grade
tumors and unfavorable patient survival in PDAC (53, 54).
E2F1 was the first identified member of the E2F family of
transcription factors. E2F activity is linked to retinoblastoma
tumor suppressor (RB)–dependent cell-cycle control. E2F
transcription factors are found downstream of growth factor
signaling cascades, acting as transcriptional activators or
repressors of genes necessary for cell cycle progression (55).
Most human tumors harbor the functionally inactivated
retinoblastoma protein, resulting in deregulated E2F1 and its
target genes are highly up-regulated in these transformed cells
(56). This up-regulation leads to the activation of cytoplasmic
(PIK3CA/AKT and RAS/MAPK/ERK) and nuclear signaling
cascades related to invasion and metastasis (54). Also, activation
of E2F1 transcription factor has been shown to induce autophagy
(57) by up-regulating the expression of the autophagy genes
LC3, ULK1 (unc-51 like autophagy activating kinase 1), ATG5
and DRAM1 (DNA damage regulated autophagy modulator 1).
The E2F1-mediated induction of LC3, ULK1, and DRAM1 is
direct (through interaction with the promoter), whereas the
up-regulation of the expression of ATG5 is indirect (58). In
this work, we provide evidence of another gene related to
autophagy that is up-regulated by E2F1. We demonstrated that
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E2F1 is able to induce autophagy in pancreatic tumor cells
and regulates VMP1-mediated autophagy by a direct binding to
VMP1 promoter.
Gemcitabine inhibits DNA synthesis via a process called
masked chain termination where gemcitabine is incorporated
into DNA via DNA polymerase α, leading to the inhibition
of DNA repair and synthesis (59). It has been shown that
E2F1 induces genes involved in DNA repair in normal
cells and in tumor cells undergoing chemotherapy through
complex formation on the promoters of these genes (54).
In this sense, BxPC-3 cells that are sensitive to the dose
of 20 µM gemcitabine did not increase the expression of
E2F1 or VMP1 during treatment. In contrast, PANC-1 cells
resistant to treatment increased the expression of E2F1, result
consistent with data of previous works (60, 61). Lai et
al. (60) have demonstrated that PANC-1 cells respond to
gemcitabine by increasing the expression of ribonucleotide
reductase M2 catalytic subunit (RRM2) through E2F1-mediated
transcriptional activation, as a DNA damage response to enhance
DNA repair capacity in these cells. Here, we demonstrated
E2F1 and VMP1 expressions are both increased in PANC-
1 cells treated with gemcitabine. Besides, pancreatic tumor
cells transfected with an expression vector for E2F1 induced
VMP1 expression and activated autophagy. Therefore, in
this study we demonstrated another mechanism activated by
E2F1 in response to chemotherapy, in which E2F1 activates
VMP1 expression and autophagy as a resistance response
to gemcitabine.
Autophagy is constitutively activated in oncogenic KRAS-
driven tumors and is necessary for the development of
these tumors (6). Previously, we identified the PI3KCA
(phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit
alpha)-AKT1 (AKT serine/threonine kinase 1) pathway as the
signaling pathway mediating the expression and promoter
activity of VMP1 in KRAS driven tumors (28). PANC-1
cells harbor a KRAS mutated allele (KRAS G12D) and these
cells present basal expression of VMP1 and autophagy. In
this work, we show that gemcitabine treatment increased
that basal VMP1 expression and autophagy in PANC-1
cells. As well as GLI3 (GLI family zinc finger 3) is the
transcription factor implicated in VMP1 promoter activation
in basal conditions in PANC-1 cells (28), E2F1 plays that
function under gemcitabine treatment. Here, we show that
down-regulation of E2F1 reduced VMP1 expression and
VMP1 promoter activity induced by gemcitabine. Besides, we
demonstrated a direct binding of E2F1 onVMP1 promoter under
gemcitabine treatment in pancreatic tumor cells. Therefore,
these data suggest VMP1 expression is regulated by different
transcription factors depending on the cellular context that
autophagy is induced. Further research will be necessary to
clarify if function or mechanisms involved in basal VMP1-
induced autophagy differs fromVMP1-induced autophagy under
gemcitabine treatment.
The regulation of gene expression depends on the
characteristic activation/repression properties of each
transcription factor, but also on functional interactions with
co-regulatory molecules. EP300 belongs to the type 3 family
of lysine acetyltransferases (KAT3) (62), and this enzyme is
involved in the regulation of important physiological processes
such as proliferation, differentiation, and apoptosis, due to its
ability to function as transcriptional coactivator interacting and
regulating more than 400 transcription factors (63, 64). However,
the role of EP300 in gene regulation is not only restricted to
its property of allowing the binding of transcription factors to
large protein complexes in the transcription machinery, but
also implies the required KAT activity for the acetylation of
transcription factors and histones that allow access to chromatin
(65). Thus, EP300 contributes to DNA repair through histone
acetylation, facilitating the recruitment of DNA repair factors
to the site of damage (66). We demonstrated that EP300
potentiates the VMP1 promoter activation by E2F1. Even,
down-regulation of EP300 impaired E2F1-mediated activation
of the VMP1 promoter in pancreatic tumor cells. These
findings demonstrate that E2F1 and p300 cooperate in VMP1
promoter regulation.
Our results agree with Hashimoto et al. (67), who have
shown that autophagy has a cytoprotective effect against
5-fluorouracil and gemcitabine in pancreatic cancer cells.
They demonstrated that inhibition of autophagy potentiates
the inhibition of PANC-1 cell proliferation by 5-fluorouracil
and gemcitabine. Here, we showed an induction of VMP1
expression and autophagy in PANC-1 and MIAPaCa-2
cells under gemcitabine treatment and down-regulation
of VMP1 expression significantly reduced autophagy
induced by gemcitabine. These data strongly suggest that
VMP1 expression is involved in PDAC chemoresistance
to gemcitabine.
In conclusion, we have identified the E2F1-EP300-
VMP1 pathway that mediates gemcitabine-induced
autophagy in pancreatic cancer cells (Figure 6E). This
pathway would be activated by gemcitabine like a
resistance mechanism. Our results point at E2F1 as a
regulatory factor modulating gemcitabine induced VMP1-
mediated autophagy in human pancreatic cancer cells
and mechanistically integrate the autophagic degradative
process into the complex network of events involved in
PDAC chemoresistance.
DATA AVAILABILITY STATEMENT
The datasets generated for this study are available on request to
the corresponding author.
AUTHOR CONTRIBUTIONS
AR designed and performed experiments, analyzed and
interpreted data, prepared figures, and wrote the manuscript.
CC performed experiments, contributed to interpret
data, and prepared figures. FR performed experiments.
VB developed analytical tools. TO developed expression
vectors. CG contributed to interpret data. MV developed the
Frontiers in Endocrinology | www.frontiersin.org 12 June 2020 | Volume 11 | Article 411
Ropolo et al. Gemcitabine-Induced Autophagy in Pancreatic Cancer
hypothesis, designed experiments, analyzed, and interpreted
data, and wrote the manuscript. All authors reviewed
the manuscript.
FUNDING
This work was supported by grants from: Consejo Nacional
de Investigaciones Científicas y Técnicas (CONICET) [PIP
2015-2017 GI−11220150100160CO]; Agencia Nacional de
Promoción Científica y Tecnológica (ANPCyT) [PICT2013-
2048; PICT2016-1032] and Universidad de Buenos
Aires [UBACYT 2014-2017 GC−20020130100764BA;
UBACyT 2018–2020−20020170100082BA].
ACKNOWLEDGMENTS
We thank all IBIMOL staff for the support received. We are
grateful to Roxana Resnik for her assistance in English. We
thank to Sociedad Argentina de Gastroenterología (SAGE) the
permission to use material presented at the Pre AGA 2015
conferences (68).
REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. (2019)
69:7–34. doi: 10.3322/caac.21551
2. Jaffee EM, Hruban RH, Canto M, Kern SE. Focus on pancreas cancer. Cancer
Cell. (2002) 2:25–8. doi: 10.1016/S1535-61080200093-4
3. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med.
(1992) 326:455–65. doi: 10.1056/NEJM199202133260706
4. Hidalgo M, Von Hoff DD. Translational therapeutic opportunities in ductal
adenocarcinoma of the pancreas. Clin Cancer Res. (2012) 18:4249–56.
doi: 10.1158/1078-0432.CCR-12-1327
5. Kimmelman AC. The dynamic nature of autophagy in cancer. Genes Dev.
(2011) 25:1999–2010. doi: 10.1101/gad.17558811
6. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, et al. Pancreatic
cancers require autophagy for tumor growth. Genes Dev. (2011) 25:717–29.
doi: 10.1101/gad.2016111
7. Yang A, Rajeshkumar NV, Wang X, Yabuuchi S, Alexander BM, Chu
GC, et al. Autophagy is critical for pancreatic tumor growth and
progression in tumors with p53 alterations. Cancer Discov. (2014) 4:905–13.
doi: 10.1158/2159-8290.CD-14-0362
8. Chawla A, Ferrone CR. Neoadjuvant therapy for resectable pancreatic
cancer: an evolving paradigm shift. Front Oncol. (2019) 9:1085.
doi: 10.3389/fonc.2019.01085
9. Ducreux M, Seufferlein T, Van Laethem JL, Laurent-Puig P, Smolenschi C,
Malka D, et al. Systemic treatment of pancreatic cancer revisited. Semin Oncol.
(2019) 46:28–38. doi: 10.1053/j.seminoncol.2018.12.003
10. Raufi AG, Manji GA, Chabot JA, Bates SE. Neoadjuvant
treatment for pancreatic cancer. Semin Oncol. (2019) 46:19–27.
doi: 10.1053/j.seminoncol.2018.12.002
11. Cao H, Le D, Yang LX. Current status in chemotherapy for advanced
pancreatic adenocarcinoma. Anticancer Res. (2013) 33:1785–91.
12. Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol.
(1995) 22:19–25.
13. Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell
death (apoptosis) of human pancreatic carcinoma is determined by Bcl-
2 content. Ann Surg Oncol. (1999) 6:279–85. doi: 10.1007/s10434-999-
0279-x





difluorodeoxycytidine (gemcitabine). Drug Resist Updat. (2002) 5:19–33.
doi: 10.1016/S1368-76460200002-X
15. Sarvepalli D, Rashid MU, Rahman AU, Ullah W, Hussain I, Hasan B, et
al. Gemcitabine: a review of chemoresistance in pancreatic cancer. Crit Rev
Oncog. (2019) 24:199–212. doi: 10.1615/CritRevOncog.2019031641
16. Zeng S, Pottler M, Lan B, Grutzmann R, Pilarsky C, Yang H.
Chemoresistance in pancreatic cancer. Int J Mol Sci. (2019) 20:E4504.
doi: 10.3390/ijms20184504
17. Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine
strategies to overcome the pathophysiological barriers of pancreatic
cancer. Nat Rev Clin Oncol. (2016) 13:750–65. doi: 10.1038/nrclinonc.20
16.119
18. Ma T, Chen W, Zhi X, Liu H, Zhou Y, Chen BW, et al. USP9X
inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting
autophagy. Cancer Lett. (2018) 436:129–38. doi: 10.1016/j.canlet.2018.08.010
19. Zeh H, Bahary N, Boone BA, Singhi AD, Miller-Ocuin JL, Normolle
DP, et al. A randomized phase II preoperative study of autophagy
inhibition with high-dose hydroxychloroquine and gemcitabine/nab-
paclitaxel in pancreatic cancer patients. Clin Cancer Res. (2020).
doi: 10.1158/1078-0432.CCR-19-4042. [Epub ahead of print].
20. Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms
and biological functions of autophagy. Dev Cell. (2004) 6:463–77.
doi: 10.1016/S1534-58070400099-1
21. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-
Migishima R, et al. Suppression of basal autophagy in neural cells
causes neurodegenerative disease in mice. Nature. (2006) 441:885–9.
doi: 10.1038/nature04724
22. Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng P, Hogan RN, et al. Autophagy
gene-dependent clearance of apoptotic cells during embryonic development.
Cell. (2007) 128:931–46. doi: 10.1016/j.cell.2006.12.044
23. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N
Engl J Med. (2013) 368:1845–46. doi: 10.1056/NEJMc1303158
24. Wilde L, Tanson K, Curry J, Martinez-Outschoorn U. Autophagy
in cancer: a complex relationship. Biochem J. (2018) 475:1939–54.
doi: 10.1042/BCJ20170847
25. Fujii S, Mitsunaga S, Yamazaki M, Hasebe T, Ishii G, Kojima
M, et al. Autophagy is activated in pancreatic cancer cells and
correlates with poor patient outcome. Cancer Sci. (2008) 99:1813–9.
doi: 10.1111/j.1349-7006.2008.00893.x
26. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics
and biology of pancreatic ductal adenocarcinoma.Genes Dev. (2006) 20:1218–
49. doi: 10.1101/gad.1415606
27. Rosenfeldt MT, O’Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A,
et al. p53 status determines the role of autophagy in pancreatic tumour
development. Nature. (2013) 504:296–300. doi: 10.1038/nature12865
28. Lo Re AE, Fernandez-Barrena MG, Almada LL, Mills LD, Elsawa SF, Lund
G, et al. Novel AKT1-GLI3-VMP1 pathway mediates KRAS oncogene-
induced autophagy in cancer cells. J Biol Chem. (2012) 287:25325–34.
doi: 10.1074/jbc.M112.370809
29. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery
and signaling regulation. Curr Opin Cell Biol. (2010) 22:124–31.
doi: 10.1016/j.ceb.2009.11.014
30. Klionsky DJ, Cregg JM, Dunn WA Jr, Emr SD, Sakai Y, Sandoval IV, et al.
A unified nomenclature for yeast autophagy-related genes. Dev Cell. (2003)
5:539–45. doi: 10.1016/S1534-5807(03)00296-X
31. Ropolo A, Grasso D, Pardo R, Sacchetti ML, Archange C, Lo Re A,
et al. The pancreatitis-induced vacuole membrane protein 1 triggers
autophagy in mammalian cells. J Biol Chem. (2007) 282:37124–33.
doi: 10.1074/jbc.M706956200
32. Vaccaro MI, Ropolo A, Grasso D, Iovanna JL. A novel mammalian trans-
membrane protein reveals an alternative initiation pathway for autophagy.
Autophagy. (2008) 4:388–90. doi: 10.4161/auto.5656
Frontiers in Endocrinology | www.frontiersin.org 13 June 2020 | Volume 11 | Article 411
Ropolo et al. Gemcitabine-Induced Autophagy in Pancreatic Cancer
33. Molejon MI, Ropolo A, Re AL, Boggio V, Vaccaro MI. The VMP1-
Beclin 1 interaction regulates autophagy induction. Sci Rep. (2013) 3:1055.
doi: 10.1038/srep01055
34. Molejon MI, Ropolo A, Vaccaro MI. VMP1 is a new player in the regulation
of the autophagy-specific phosphatidylinositol 3-kinase complex activation.
Autophagy. (2013) 9:933–5. doi: 10.4161/auto.24390
35. Grasso D, Ropolo A, Lo Re A, Boggio V, Molejon MI, Iovanna JL, et
al. Zymophagy, a novel selective autophagy pathway mediated by VMP1-
USP9x-p62, prevents pancreatic cell death. J Biol Chem. (2011) 286:8308–24.
doi: 10.1074/jbc.M110.197301
36. Pardo R, Lo Ré A, Archange C, Ropolo A, Papademetrio DL, Gonzalez
CD, et al. Gemcitabine induces the VMP1-mediated autophagy pathway to
promote apoptotic death in human pancreatic cancer cells. Pancreatology.
(2010) 10:19–26. doi: 10.1159/000264680
37. Grasso D, Sacchetti ML, Bruno L, Lo Ré A, Iovanna JL, Gonzalez CD, et al.
Autophagy and VMP1 expression are early cellular events in experimental
diabetes. Pancreatology. (2009) 9:81–8. doi: 10.1159/000178878
38. Jiang PH, Motoo Y, Vaccaro MI, Iovanna JL, Okada G, Sawabu N.
Expression of vacuole membrane protein 1 (VMP1) in spontaneous
chronic pancreatitis in the WBN/Kob rat. Pancreas. (2004) 29:225–30.
doi: 10.1097/00006676-200410000-00008
39. Vaccaro MI, Grasso D, Ropolo A, Iovanna JL, Cerquetti MC. VMP1
expression correlates with acinar cell cytoplasmic vacuolization in arginine-
induced acute pancreatitis. Pancreatology. (2003) 3:69–74. doi: 10.1159/0000
69150
40. Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding
pancreatic cancer proliferation. Trends Biochem Sci. (2014) 39:91–100.
doi: 10.1016/j.tibs.2013.12.004
41. Gilabert M, Vaccaro MI, Fernandez-Zapico ME, Calvo EL, Turrini O, Secq
V, et al. Novel role of VMP1 as modifier of the pancreatic tumor cell
response to chemotherapeutic drugs. J Cell Physiol. (2013) 228:1834–43.
doi: 10.1002/jcp.24343
42. Rodriguez ME, Catrinacio C, Ropolo A, Rivarola VA, Vaccaro MI. A novel
HIF-1alpha/VMP1-autophagic pathway induces resistance to photodynamic
therapy in colon cancer cells. Photochem Photobiol Sci. (2017) 16:1631–42.
doi: 10.1039/C7PP00161D
43. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf
kinase inhibitor. Endocr Relat Cancer. (2001) 8:219–25. doi: 10.1677/erc.0.00
80219
44. Wei L, Ye H, Li G, Lu Y, Zhou Q, Zheng S, et al. Cancer-associated
fibroblasts promote progression and gemcitabine resistance via the SDF-
1/SATB-1 pathway in pancreatic cancer. Cell Death Dis. (2018) 9:1065.
doi: 10.1038/s41419-018-1104-x
45. Wang X, Yin L, Yang L, Zheng Y, Liu S, Yang J, et al. Silencing ubiquitin-
conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal
transition in pancreatic ductal adenocarcinoma. FEBS J. (2019) 286:4889–909.
doi: 10.1111/febs.15134
46. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo
Arozena A, et al. Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy. (2016) 12:1–222.
doi: 10.1080/15548627.2015.1100356
47. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T,
et al. LC3, a mammalian homologue of yeast Apg8p, is localized in
autophagosome membranes after processing. EMBO J. (2000) 19:5720–8.
doi: 10.1093/emboj/19.21.5720
48. Feng Y, He D, Yao Z, Klionsky DJ. The machinery of macroautophagy. Cell
Res. (2014) 24:24–41. doi: 10.1038/cr.2013.168
49. DeGregori J, Johnson DG. Distinct and overlapping roles for E2f family
members in transcription, proliferation and apoptosis. Curr Mol Med. (2006)
6:739–48. doi: 10.2174/1566524010606070739
50. Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP, et al.
Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic
review and network meta-analysis. Lancet Oncol. (2013) 14:1095–103.
doi: 10.1016/S1470-20451370388-7
51. Elgendy M, Sheridan C, Brumatti G, Martin SJ. Oncogenic Ras-
induced expression of Noxa and Beclin-1 promotes autophagic cell
death and limits clonogenic survival. Mol Cell. (2011) 42:23–35.
doi: 10.1016/j.molcel.2011.02.009
52. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, et
al. Activated Ras requires autophagy to maintain oxidative metabolism and
tumorigenesis. Genes Dev. (2011) 25:460–70. doi: 10.1101/gad.2016311
53. Schild C, Wirth M, Reichert M, Schmid RM, Saur D, Schneider G.
PI3K signaling maintains c-myc expression to regulate transcription
of E2F1 in pancreatic cancer cells. Mol Carcinog. (2009) 48:1149–58.
doi: 10.1002/mc.20569
54. Engelmann D, Putzer BM. The dark side of E2F1: in transit beyond apoptosis.
Cancer Res. (2012) 72:571–5. doi: 10.1158/0008-5472.CAN-11-2575
55. Putzer BM, Engelmann D. E2F1 apoptosis counterattacked: evil strikes back.
Trends Mol Med. (2013) 19:89–98. doi: 10.1016/j.molmed.2012.10.009
56. Uchida C. The retinoblastoma protein: functions beyond the G1-S regulator.
Curr Drug Targets. (2012) 13:1622–32. doi: 10.2174/138945012803529938
57. Korah J, Canaff L, Lebrun JJ. The retinoblastoma tumor suppressor
protein (pRb)/E2 promoter binding factor 1 (E2F1) pathway as a novel
mediator of TGFβ-induced autophagy. J Biol Chem. (2016) 291:2043–54.
doi: 10.1074/jbc.M115.678557
58. Polager S, OfirM, Ginsberg D. E2F1 regulates autophagy and the transcription
of autophagy genes. Oncogene. (2008) 27:4860–4. doi: 10.1038/onc.2008.117
59. Soo RA, Yong WP, Innocenti F. Systemic therapies for pancreatic cancer–
the role of pharmacogenetics. Curr Drug Targets. (2012) 13:811–28.
doi: 10.2174/138945012800564068
60. Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, et al. Targeting
the Warburg effect with a novel glucose transporter inhibitor to overcome
gemcitabine resistance in pancreatic cancer cells. Carcinogenesis. (2014)
35:2203–13. doi: 10.1093/carcin/bgu124
61. Zhu X, Shi C, Peng Y, Yin L, TuM, Chen Q, et al. Thymidine kinase 1 silencing
retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis.
Cell Prolif. (2018) 51:e12428. doi: 10.1111/cpr.12428
62. Yuan LW, Giordano A. Acetyltransferase machinery conserved in p300/CBP-
family proteins. Oncogene. (2002) 21:2253–60. doi: 10.1038/sj.onc.1205283
63. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional
bridges and scaffolds. J Cell Sci. (2001) 114:2363–73.
64. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem
Pharmacol. (2004) 68:1145–55. doi: 10.1016/j.bcp.2004.03.045
65. Dancy BM, Cole PA. Correction to protein lysine acetylation by p300/CBP.
Chem Rev. (2016) 116:8314. doi: 10.1021/acs.chemrev.6b00351
66. Ogiwara H, Kohno T. CBP and p300 histone acetyltransferases contribute to
homologous recombination by transcriptionally activating the BRCA1 and
RAD51 genes. PLoS One. (2012) 7:e52810. doi: 10.1371/journal.pone.0052810
67. Hashimoto D, Blauer M, Hirota M, Ikonen NH, Sand J, Laukkarinen J.
Autophagy is needed for the growth of pancreatic adenocarcinoma and
has a cytoprotective effect against anticancer drugs. Eur J Cancer. (2014)
50:1382–90. doi: 10.1016/j.ejca.2014.01.011
68. Vaccaro MI, Ropolo A, Giovenco M, Catrinacio C, Renna F, Grasso
D, et al. Autophagy mediates resistance of pancreatic cancer cells to
chemotherapy through a novel E2F1-p300-VMP1 pathway. Gastroenterology.
(2015) 148(Suppl 1):S-341. doi: 10.1016/S0016-50851531135-5
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Ropolo, Catrinacio, Renna, Boggio, Orquera, Gonzalez and
Vaccaro. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Endocrinology | www.frontiersin.org 14 June 2020 | Volume 11 | Article 411
